- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ARCELLX Aktie jetzt für 0€ handeln | |||||
| Mi | Kite and Arcellx close multiple myeloma collaboration agreement | - | PMLiVE | ||
| 30.01. | Gilead, Arcellx close agreement on developing T-cell therapy for multiple myeloma | 12 | Seeking Alpha | ||
| 30.01. | Arcellx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.01. | Arcellx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 16.12.22 | Arcellx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.12.22 | Why The Arcellx (ACLX) Stock Increased 1.78% | - | pulse2.com | ||
| 12.12.22 | Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology | 19 | Zacks | ||
| 12.12.22 | Kite and Arcellx partner to develop and commercialise multiple myeloma candidate | - | PMLiVE | ||
| 09.12.22 | Gilead Sciences Gets a Shot at Next-Gen Cell Therapy With $325M Arcellx Alliance | 11 | MedCity News | ||
| 09.12.22 | Gilead, Arcellx team up on anti-BCMA CAR-T as biotech touts a 100% response rate at ASH22 | 14 | Endpoints News | ||
| 09.12.22 | Gilead lands new cell therapy for Kite in $225M Arcellx deal, providing global scale for future J&J-Legend showdown | 9 | FierceBiotech | ||
| 09.12.22 | UpHealth, Arcellx top healthcare gainers; Autolus, Pharvaris lead losers pack | 3 | Seeking Alpha | ||
| 09.12.22 | Arcellx rises ~25% on collaboration deal with Gilead's Kite for lead myeloma candidate | 6 | Seeking Alpha | ||
| 09.12.22 | Arcellx Announces Positive Response From CART-dd BCMA Phase 1 Trial Of ACLX-002 In Multiple Myeloma | 1 | RTTNews | ||
| 09.12.22 | Kite, Arcellx To Co-develop, Co-commercialize Arcellx's Lead Product Candidate, CART-ddBCMA | 581 | AFX News | FOSTER CITY (dpa-AFX) - Kite, a Gilead Company (GILD), and Arcellx, Inc. (ACLX), announced a global strategic collaboration to co-develop and co-commercialize Arcellx's lead late-stage product... ► Artikel lesen | |
| 09.12.22 | Arcellx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.11.22 | Arcellx GAAP EPS of -$2.12 | - | Seeking Alpha | ||
| 14.11.22 | Arcellx, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.11.22 | Arcellx, Inc. - 10-Q/A, Quarterly Report | - | SEC Filings | ||
| 09.11.22 | Arcellx, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIR BIOTECHNOLOGY | 30,140 | +0,77 % | Vir Biotechnology, Inc.: Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor | - Dr. De Backer to assume CEO role on April 3, 2023 - - Upon his retirement as CEO, Dr. Scangos will transition to an advisory role through June 2, 2023 and will continue providing strategic counsel... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 26,000 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Pricing of Upsized Initial Public Offering | SAN FRANCISCO and SHANGHAI, China, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule... ► Artikel lesen | |
| KARUNA THERAPEUTICS | 191,99 | -1,32 % | Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing' | ||
| BEAM THERAPEUTICS | 48,450 | -0,70 % | Analyst Ratings for Beam Therapeutics | ||
| PROMETHEUS BIOSCIENCES | 108,68 | +0,23 % | Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock | SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 31,690 | -6,93 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights | - Presented Positive Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 - - Expanded... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 49,340 | +1,02 % | Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates | WAKIX® (pitolisant) Net Revenue of $117.2 Million for Third Quarter 2022 Increase of ~45% vs. the Same Period in 2021 Average Number of Patients on WAKIX Increased to ~4,600 Prader-Willi Syndrome... ► Artikel lesen | |
| RELAY THERAPEUTICS | 22,070 | -3,03 % | Relay Therapeutics, Inc.: Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day | ||
| KYMERA THERAPEUTICS | 37,150 | -4,13 % | Kymera Therapeutics, Inc.: Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23 | ||
| AMYLYX PHARMACEUTICALS | 36,640 | -0,97 % | Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today reported financial results for the quarter ended September 30, 2022.
"The... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 9,640 | +2,88 % | Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB | SALT LAKE CITY, Oct. 25, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced today that it... ► Artikel lesen | |
| VERVE THERAPEUTICS | 23,290 | -3,00 % | Being Cautious On Regulatory/Commercial Path, This Analyst Initiates Coverage On Verve Therapeutics | ||
| IMMUNOVANT | 17,750 | -2,95 % | Immunovant Inc.: Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022 | A Phase 1 clinical trial of IMVT-1402 is on track to be initiated in early calendar year 2023A Phase 3 clinical trial of batoclimab in thyroid eye disease (TED) and a Phase 2b clinical trial in chronic... ► Artikel lesen | |
| CINCOR PHARMA | 29,160 | +0,41 % | AstraZeneca Commencs Tender Offer To Buy CinCor Pharma | LONDON (dpa-AFX) - British drug major AstraZeneca Plc. (AZN.L, AZN) Monday said it is commencing a tender offer to buy all shares of CinCor Pharma, Inc. (CINC), a US-based clinical-stage biopharmaceutical... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 16,670 | +1,96 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
